{
    "clinical_study": {
        "@rank": "139585", 
        "arm_group": {
            "arm_group_label": "Naloxone, Kisspeptin, GnRH", 
            "arm_group_type": "Experimental", 
            "description": "The study will involve 3 visits:\nOutpatient screening visit\nInpatient admission where subjects receive an intravenous infusion of naloxone, intravenous doses of kisspeptin 112-121, and intravenous doses of Gonadotropin Releasing Hormone (GnRH)\nOutpatient follow-up visit"
        }, 
        "brief_summary": {
            "textblock": "The investigators are seeking healthy volunteers and volunteers with reproductive disorders\n      for the study of the role of dynorphin in the reproductive system. Dynorphin is a naturally\n      occurring opioid hormone that is blocked by naloxone.\n\n      We hypothesize that naloxone, by blocking dynorphin, will stimulate production of GnRH and\n      kisspeptin, 2 other naturally occurring reproductive hormones."
        }, 
        "brief_title": "Neuropeptides in Human Reproduction", 
        "condition": "Hypogonadotropic Hypogonadism", 
        "condition_browse": {
            "mesh_term": "Hypogonadism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ages 21-40 (healthy men and regularly cycling women) OR ages 18-75 (men and women\n             with hypogonadotropic hypogonadism (HH))\n\n          -  Normal blood pressure (systolic BP <140 mm Hg, diastolic BP <90 mm Hg)\n\n          -  White blood cell, plates, prolactin, and thyroid stimulating hormone (TSH)within\n             90%-110% of laboratory reference range\n\n          -  Negative urine drug screen panel\n\n          -  Hemoglobin:\n\n               1. For healthy men and healthy regularly cycling women: normal\n\n               2. For men and women with HH: No less than 0.5 gm/dL below the lower limit of the\n                  reference range for normal women\n\n          -  Blood urea nitrogen (BUN), creatinine, liver function tests not elevated\n\n          -  For healthy subjects: Normal reproductive function and history\n\n          -  For healthy subjects: Body Mass Index (BMI) 18.5-30kg/m2\n\n          -  For subjects with HH: All medical conditions stable and well controlled\n\n        Exclusion Criteria:\n\n          -  History of medication reaction requiring emergency medical attention\n\n          -  Illicit drug use\n\n          -  Consumption of more than 10 alcoholic drinks per week\n\n          -  Difficulty with blood draws\n\n          -  Currently seeking fertility, breastfeeding, or pregnant\n\n          -  For healthy subjects: history of chronic disease and prescription medication use\n             (with the exception of seasonal allergy medication)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "128", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01952782", 
            "org_study_id": "2013P001543"
        }, 
        "intervention": [
            {
                "arm_group_label": "Naloxone, Kisspeptin, GnRH", 
                "description": "Subjects will receive up to 10 intravenous doses of kisspeptin 112-121", 
                "intervention_name": "Kisspeptin 112-121", 
                "intervention_type": "Drug", 
                "other_name": "Metastin 45-54"
            }, 
            {
                "arm_group_label": "Naloxone, Kisspeptin, GnRH", 
                "description": "Subjects will receive one intravenous dose of naloxone followed by an intravenous infusion of naloxone.", 
                "intervention_name": "Naloxone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Naloxone, Kisspeptin, GnRH", 
                "description": "Subjects will receive up to 10 doses of intravenous Gonadotropin Releasing Hormone (GnRH)", 
                "intervention_name": "Gonadotropin Releasing Hormone (GnRH)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hormones", 
                "Naloxone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 13, 2013", 
        "location": {
            "contact": {
                "email": "cli17@partners.org", 
                "last_name": "Cindy Li, BA", 
                "phone": "617-724-1083"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Stephanie B Seminara, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Yee-Ming Chan, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Maragret Lippincott, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Neuropeptides in Human Reproduction", 
        "overall_contact": {
            "email": "cli17@partners.org", 
            "last_name": "Cindy Li, BA", 
            "phone": "617-724-1083"
        }, 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Stephanie B Seminara, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Data and Safety Monitoring Board", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Luteinizing Hormone (LH) level", 
            "safety_issue": "No", 
            "time_frame": "6 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01952782"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Stephanie B. Seminara, MD", 
            "investigator_title": "Associate in Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Follicle Stimulating Hormone (FSH) level", 
                "safety_issue": "No", 
                "time_frame": "6 hours"
            }, 
            {
                "measure": "Testosterone (Males)", 
                "safety_issue": "No", 
                "time_frame": "6 hours"
            }, 
            {
                "measure": "Estradiol (Females)", 
                "safety_issue": "No", 
                "time_frame": "6 hours"
            }, 
            {
                "measure": "Complete Blood Count (CBC)", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Blood Urea Nitrogen (BUN)", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Creatinine", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Liver Function Studies", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }
        ], 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}